EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Safety and Efficacy of CT-Guided Iodine-125 Brachytherapy for Portal Vein Tumor Thrombus in Hepatocellular Carcinoma

Zhenkang Qiu, Chunpeng Yu, Xiaofei Qiu, Qun Li, Jian Li, Zhao Chen, Shuai Chang, Shuo Zhang, Gang Fan, Song Wang

Academic Radiology · 2023

DOI: 10.1016/j.acra.2023.02.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Academic Radiology, 2023. Verfasst von Zhenkang Qiu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Medical Center, The Affiliated Hospital of Qingdao University, 16 Jiangsu, 266003, Qingdao, Shandong Province, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Brachytherapy, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE AND OBJECTIVES: Portal vein tumor thrombus (PVTT) seriously reduces the survival of patients with hepatocellular carcinoma (HCC). CT-guided iodine-125 (125I) brachytherapy has the advantage of a high local control rate and is minimally invasive. This study aims to evaluate the safety and efficacy of 125I brachytherapy for treating PVTT in HCC patients. MATERIALS AND METHODS: Thirty-eight patients diagnosed with HCC complicated with PVTT and treated with 125I brachytherapy for PVTT were included in this retrospective study. The local tumor control rate, local tumor progression-free survival, and overall survival (OS) were analyzed. Cox proportional hazards regression analysis was performed to identify predictors affecting survival. RESULTS: The local tumor control rate was 78.9% (30/38). The median local tumor progression-free survival was 11.6 (95% confidence interval [CI]: 6.7, 16.5) months, and the median overall survival was 14.5 (95% CI: 9.2, 19.7) months. Multivariate Cox analysis showed that age

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBrachytherapyChemoembolization, TherapeuticThrombosisHumansMiddle AgedRetrospective StudiesPortal VeinTreatment OutcomeTomography, X-Ray ComputedIodine Radioisotopes

Stichwörter der Autor:innen

Hepatocellular carcinomaIodine-125Portal vein tumor thrombuslocal tumor control rate

Substanzen

Iodine-125Iodine Radioisotopes

Autor:innen und Institutionen

  • Interventional Medical Center, The Affiliated Hospital of Qingdao University, 16 Jiangsu, 266003, Qingdao, Shandong Province, China.
  • Qingdao Municipal Center For Disease Control & Prevention, Qingdao Institute of Preventive Medicine, Qingdao, Shandong Province, China.
  • Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Department of Interventional Medicine, Jimo District Qingdao Hospital of Traditional Chinese Medicine, Qingdao, Shandong, China.
  • Interventional Medical Center, The Affiliated Hospital of Qingdao University, 16 Jiangsu, 266003, Qingdao, Shandong Province, China. Electronic address: derekqyfy@126.com.

Zitieren

APA

Qiu, Z., Yu, C., Qiu, X., Li, Q., Li, J., Chen, Z., Chang, S., Zhang, S., Fan, G., & Wang, S. (2023). Safety and Efficacy of CT-Guided Iodine-125 Brachytherapy for Portal Vein Tumor Thrombus in Hepatocellular Carcinoma. Academic Radiology. https://doi.org/10.1016/j.acra.2023.02.006

Vancouver

Qiu Z, Yu C, Qiu X, Li Q, Li J, Chen Z, et al. Safety and Efficacy of CT-Guided Iodine-125 Brachytherapy for Portal Vein Tumor Thrombus in Hepatocellular Carcinoma. Academic Radiology. 2023. doi:10.1016/j.acra.2023.02.006

BibTeX
@article{Qiu2023,
  author = {Qiu, Zhenkang and Yu, Chunpeng and Qiu, Xiaofei and Li, Qun and Li, Jian and Chen, Zhao and Chang, Shuai and Zhang, Shuo and Fan, Gang and Wang, Song},
  title = {Safety and Efficacy of CT-Guided Iodine-125 Brachytherapy for Portal Vein Tumor Thrombus in Hepatocellular Carcinoma},
  journal = {Academic Radiology},
  year = {2023},
  doi = {10.1016/j.acra.2023.02.006}
}
Kostenlos starten →